Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ORIC Pharmaceuticals, Inc.

Market Cap 810M 699M 644M 603M 1.13B 76.94B 1.15B 7.61B 2.97B 37.45B 3.04B 2.97B 130B P/E Ratio 2026 *
-5.38x
P/E Ratio 2027 * -5.03x
Enterprise Value 700M 605M 557M 522M 978M 66.55B 993M 6.58B 2.57B 32.39B 2.63B 2.57B 112B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.15%
Yield 2026 *
-
Yield 2027 * -
1 week-2.97%
Current month-7.30%
1 month-10.75%
3 months-37.72%
6 months-19.93%
Current year-2.52%
1 week 6.38
Extreme 6.382
7.22
1 month 6.31
Extreme 6.306
7.79
3 years 3.7
Extreme 3.7
14.9
5 years 2.2
Extreme 2.2
21.2
Manager TitleAgeSince
Chief Executive Officer 47 2018-05-06
Director of Finance/CFO 52 2019-08-31
Chief Tech/Sci/R&D Officer - 2025-08-17
Director TitleAgeSince
Chairman 68 2018-03-06
Director/Board Member 47 2018-05-06
Director/Board Member 62 2020-01-31
Change 5-day change 1-year change 3-year change Capi.($)
+6.05%-2.97%-20.87%+41.30% 810M
+1.03%+2.30%+54.92%+111.78% 55.58B
+2.72%+3.06%+53.28%+47.85% 43.47B
+0.86%+2.40%-14.04%-17.85% 22.64B
+1.48%+3.83%+0.98%+401.70% 20.96B
+3.81%-4.13%+16.62%-30.70% 15.79B
+0.15%+0.50%+9.10%-40.04% 15.3B
-0.41%+1.01%+27.41%+178.84% 13.45B
+5.27%+6.41%+21.05% - 11.74B
+1.61%+1.17%+90.79%+212.97% 10.96B
Average +1.83%+0.26%+23.92%+100.65% 23.32B
Weighted average by Cap. +1.72%+1.60%+33.54%+100.45%

Financials

2026 *2027 *
Net sales - -
Net income -154M -133M -122M -115M -215M -14.62B -218M -1.45B -564M -7.12B -577M -565M -24.64B -180M -156M -144M -134M -252M -17.16B -256M -1.7B -661M -8.35B -677M -663M -28.91B
Net Debt -109M -94.42M -87.01M -81.45M -153M -10.39B -155M -1.03B -401M -5.06B -410M -402M -17.51B -231M -200M -184M -172M -323M -21.99B -328M -2.17B -848M -10.7B -868M -850M -37.06B
Logo ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Employees
-
Date Price Change
26-06-12 7.068 +5.08%
26-06-11 6.726 +3.51%
26-06-10 6.498 -4.47%
26-06-09 6.802 +4.13%
26-06-08 6.532 -0.09%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
7.820USD
Average target price
19.93USD
Spread / Average Target
+154.90%

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!